/biz/ - Business & Finance

SRNE combines:
>one of the most active and promising pipelines in the COVID space
>a potentially transformative non-opioid pain pipeline
>a deep oncology pipeline

Near-term menu:
>EUA for COVI-STIX (a 15-minute nasal swab antigen test for SARS-CoV-2) has already been filed in the US and Mexico, and the test could be launched as early as 1H21. This could rapidly approach $500M in sales as soon as 2022.
>SRNE's 8-minute SARS-CoV-2 antibody test COVID-TRACK could swiftly follow in its footsteps with an EUA anticipated to be filed in the year’s first half. Another $500million+ near term opportunity.
>Two neutralizing antibody treatments, COVI-DROPS and COVI-AMG, against SARS-CoV-2, could be launched in 2022. Each of these have the potential to bring in more than $500 million in sales.
>Phase 3 data for SP-102 (sciatica pain candidate) should be available this year.
>RTX for OsteoArthritis knee pain and intractable cancer pain will kick-off Phase 2 and Phase 3 studies, respectively, in 2021. Both target substantial market opportunities.
>Abivertinib (for non-small-cell lung cancer (NSCLC) and B-cell lymphomas), currently in Phase 3 trials in China with top line data anticipated in 1H21.

>Sorrento Therapeutics Inc
>NASDAQ: SRNE
Not wanting a 3x or 4x. Stay poor faggots.

>Sorrento Therapeutics Inc
>NASDAQ: SRNE
Did you miss CLF? This is the next stock.

>Sorrento Therapeutics Inc
>NASDAQ: SRNE
>30k USD bag
Post your suicide stock.

>>26031794
>SRNE
>Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir™, Seprehvec™) and a Tyrosine Kinase Inhibitor (Abivertinib).
>Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™, COVI-DROPS™, SALICYN – 30 and MESENCHYMAL STEM CELL; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
>Sorrento's commitment to developing and commercializing medicines for Saving-Life™ and Improving-Life™ is also demonstrated by our efforts to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and by ZTlido® (lidocaine topical system) 1.8%, for post-herpetic neuralgia (PHN). Resiniferatoxin is completing (i) a phase IB trial for intractable pain associated with cancer; and (ii) a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.

>Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir™, Seprehvec™) and a Tyrosine Kinase Inhibitor (Abivertinib).
>Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™, COVI-AMG™, COVI-DROPS™, SALICYN – 30 and MESENCHYMAL STEM CELL; and diagnostic test solutions, including COVI-TRACK™, COVI-STIX™ and COVI-TRACE™.
>Sorrento's commitment to developing and commercializing medicines for Saving-Life™ and Improving-Life™ is also demonstrated by our efforts to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (RTX), and by ZTlido® (lidocaine topical system) 1.8%, for post-herpetic neuralgia (PHN). Resiniferatoxin is completing (i) a phase IB trial for intractable pain associated with cancer; and (ii) a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.

>>26028247
>Sorrento Therapeutics Inc
>2.5x

-teleports behind you in a lambo-
heh nothing personal kid. I am rich off of sorrento. I have made it. what kind of business should I purchase to make even more money? I already own a bunch of duplexes and triplexes after cashing out my winnings but I want more, would a franchise be a good idea or should I make my own kind of restaurant?